Brosseau, Jean-Philippe

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de biochimie et de génomique fonction.

Coordonnées

Courriel


819-821-8000, poste 72477


Site Web

Diplômes

(2019) The contribution of microenvironment to neurofibromagenesis. Post-doctorate (Post-doctorate). University of Texas Southwestern Medical Center.

(2012) Detection, Functional Annotation, and Regulationof Splicing Isoforms AssociatedWith Ovarian Cancer. Doctorate (Philosophy doctor). Université de Sherbrooke.

(2006) Design, Synthesis, and Pharmacological Characterization of Fluorescein-derived Endothelin Antagonists BQ-123 and BQ-788. Master's Thesis (Master in Science). Université de Sherbrooke.

(2002) N/A. Bachelor's (Bachelor in Science). Université de Sherbrooke.

Expérience académique

(2020-2023) Emerging Researcher. Centre de recherche du centre hospitalier universitaire de Sherbrooke.

(2020-2023) Adjunct Professor. Université de Sherbrooke.

(2019-2020) Assistant Instructor. University of Texas.

(2014-2019) Postdoctoral Fellow. University of Texas.

(2013-2014) Postdoctoral Fellow. Max-Planck-Institute.

(2006-2012) Ph.D. student. Université de Sherbrooke.

(2003-2006) M.Sc. student. Université de Sherbrooke.

Présentation

Sujets de recherche

Bioactive Molecules, Cancer Diagnosis and Detection, Gene Regulation and Expression, Genomics.

Disciplines de recherche

Biochemistry, Cell Biology, Genetics, Molecular Biology, Oncology, Pharmacology.

Mots-clés

gene expression regulation, alternative splicing, Benign tumor, Cancer markers, Fibroblast Biology, Functional Genomic, Hereditary cancer, Myofibroblast, neurofibromatosis, RNA binding protein, tumor microenvironment, tumor suppressor gene.

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2018) Young Investigator Award. Children's Tumor Foundation. (Prize / Award).
  • 1st prize poster competition. Colloque Santé Vasculaire et Rénale. CHU de Québec - CHUL. (Prize / Award).
  • 3rd prize. Symposium de Biochimie de l'Université de Sherbrooke. Université de Sherbrooke. (Prize / Award).
  • PhD scholarship. Université de Sherbrooke. (Prize / Award).

Financement

Grant. (Awarded). Principal Investigator. The NF1 Microenvironment: Friend or Foe?. Department of Defense (USA). Fiscal Year 2018 Neurofibromatosis Research Program Early Investigator Research Award. 200000 $ (2019-2021).

Fellowship. (Completed). Principal Applicant. Fibroblasts: The missing gap in neurofibromatosis. Children's Tumor Foundation. Young Investigtor Award. 100500 $ (2016-2018).

Scholarship. (Completed). Principal Applicant. N/A. University of Sherbrooke. 8000 $ (2006-2012).

Publications

Articles de revue

  • Yao H#, Lan J#, Li C#, Shi H#, BROSSEAU JP , Wang H , Lu H , Fang C , Zhang Y , Liang L , Zhou X , Wang C , Xue Y , Cui Y , Xu J. (2019). # These authors contribute equally. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nature Biomedical Engineering, 3(4), 306-317. (Published).
  • Chen Z, Mo J#, BROSSEAU JP#, Shipman T, Wang Y, Liao CP, Allaway RJ, Gosline SJC, Guinney J and Le LQ. (2019). # These authors contribute equally. Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. Cancer Discovery, 9(1), 114-29. DOI. (Published).
  • BROSSEAU JP$ and Le LQ$. (2019). $ Co-corresponding author. Heterozygous Tumor Suppressor Microenvironment in Cancer Development. Trends in Cancer, 9, 541-6. (Published).
  • BROSSEAU JP#, Liao CP#, Wang Y, Ramani V, Vandergriff T, Lee M*, Patel A*, Ariizumi K and Le LQ. (2018). # These authors contribute equally. * Highly Qualified Trained Personnel. NF1 Heterozygosity Fosters de Novo Tumorigenesis, but Impairs Malignant Transformation. Nature Communications, 9(1), 5014-24. DOI. (Published).
  • BROSSEAU JP#, Pichard DC#, Legius E, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma S, Brownell I, and Le LQ. (2018). # These authors contribute equally. The Biology of Cutaneous Neurofibroma. Neurology, 91(Suppl 1), S14-20. DOI. (Published).
  • Liao CP, Booker R, BROSSEAU JP, Chen Z, Mo J, Tchegnon E, Wang Y, Clapp W, and Le LQ. (2018). Contribution of Inflammation and Tumor Microenvironment to Neurofibroma Tumorigenesis. Journal of Clinical Investigation, 128(7), 2848-61. DOI. (Published).
  • BROSSEAU JP. (2018). Splicing Isoform-Specific Functional Genomic in Cancer Cells. Applied Cancer Research, 38(18), 1-11. DOI. (Published).
  • BROSSEAU JP, Lucier JF, Lamarche AA, Shkreta L, Gendron D, Lapointe E, Thibault P, Paquet E, Perreault JP, Elela SA, and Chabot B. (2014). Redirecting Splicing With Interfering and Stimulating Bifunctional Oligonucleotides. Nucleic Acids Research, 42(6), e40. DOI. (Published).
  • BROSSEAU JP, Lucier JF, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Chabot B, Perreault JP, and Elela SA. (2014). Tumor Microenvironment Associated Modifications of Alternative Splicing. RNA, 20(2), 189-201. DOI. (Published).
  • Lecka J , Gillerman I , Fausther M , Salem M , Munkonda MN , BROSSEAU JP , Cadot C , Martín-Satué M , d'Orléans-Juste P , Rousseau E , Poirier D , Künzli B , Fischer B , Sévigny J. (2013). 8-BuS-ATP derivatives as specific NTPDase1 inhibitors. British journal of pharmacology, 169(1), 179-96. DOI. (Published).
  • Venables JP , BROSSEAU JP , Gadea G , Klinck R , Prinos P , Beaulieu JF , Lapointe E , Durand M , Thibault P , Tremblay K , Rousset F , Tazi J , Abou Elela S , Chabot B. (2013). RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Molecular and Cellular Biology, 33(2), 396-405. (Published).
  • Prinos P , Garneau D , Lucier JF , Gendron D , Couture S , Boivin M , Brosseau JP , Lapointe E , Thibault P , Durand M , Tremblay K , Gervais-Bird J , Nwilati H , Klinck R , Chabot B , Perreault JP , Wellinger RJ , Elela SA. (2011). Alternative splicing of SYK regulates mitosis and cell survival. Nature structural & molecular biology, 18(6), 673-9.
  • Brosseau JP , Lucier JF , Lapointe E , Durand M , Gendron D , Gervais-Bird J , Tremblay K , Perreault JP , Elela SA. (2010). High-throughput quantification of splicing isoforms. RNA (New York, N.Y.), 16(2),
  • Brosseau JP , Neugebauer WA , Gobeil F , D'Orléans-Juste P. (2009). Design, synthesis and pharmacological characterization of fluorescein-derived endothelin antagonists Bq-123 and Bq-788. Advances in experimental medicine and biology, 611,
  • Venables JP , Klinck R , Bramard A , Inkel L , Dufresne-Martin G , Koh C , Gervais-Bird J , Lapointe E , Froehlich U , Durand M , Gendron D , Brosseau JP , Thibault P , Lucier JF , Tremblay K , Prinos P , Wellinger RJ , Chabot B , Rancourt C , Elela SA. (2008). Identification of alternative splicing markers for breast cancer. Cancer research, 68(22),
  • Brosseau JP , D'Orléans-Juste P , Neugebauer WA. (2005). Development of an efficient strategy for the synthesis of the ETB receptor antagonist BQ-788 and some related analogues. Peptides, 26(8), DOI. (Published).

Chapitres de livre

  • BROSSEAU JP. (2020). Regulations on messenger RNA: wires and nodes. Xu J. Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy (Chapter 11). Singapore : SpringerNature. (In Press).
  • BROSSEAU JP and Abou Elela S. (2013). The merit of alternative messenger RNA splicing as a new mine for the next generation ovarian cancer biomarkers. Ivan Diaz-Padilla Ovarian Cancer - A Clinical and Translational update (327-48). United Kingdom : Intech Open. (Published).

Autres contributions

Gestion d'évènements

  • Co-Funder and Organizer. (2016-2019). Dermatology Departmental Meetings. (Seminar).
  • Co-chair session moderator. (2019). 3rd international cancer conference and Expo. (Conference).
  • Treasurer. (2004). Jeux de Chimie 2004. (Association).
  • Treasurer. (2002). Colloque de chimie de l’Université de Sherbrooke. (Conference).

Présentations

  • (2019). Extracellular Matrix Reorganization in Neurofibroma. UTSouthwestern Postdoc Work in progress seminar serie. Dallas, United States.
  • (2019). Extracellular Matrix Reorganization in Neurofibroma. UTSouthwestern Postdoc Work In Progress Seminar Series. Dallas, United States.
  • (2019). Hereditary Benign Tumor Syndrome: A model for cancer prevention. Invited by the department of nuclear medicine and radiobiology. Université de Sherbrooke. Sherbrooke, Canada.
  • (2019). Hereditary Cancer Syndrome: Thinking outside the box. Invited by the Centre de recherche du CHU de Quebec-Université Laval. Quebec, Canada.
  • (2019). Hereditary Cancer Syndrome: Thinking outside the box. Invited by the Center of Excellence in Orphan Disease Research - UQAM. Montreal, Canada.
  • (2019). Hereditary Cancer Syndrome: Thinking outside the box. UTSouthwestern Cancer Biology Work in progress seminar serie. Dallas, United States.
  • (2019). Hereditary Cancer Syndrome: Thinking outside the box. UTSouthwestern Cancer Biology Work In Progress Seminar Series. Dallas, United States.
  • * Highly Qualified Trained Personnel. Lee M*, Brosseau JP, and Le LQ. (2019). Histological characterization and development of targeted strategies for neurofibroma tumor microenvironment (poster). UTSouthwestern Summer Research Fellowship (SURF) Program. Dallas, United States.
  • * Highly Qualified Trained Personnel Hicks WH*, Brosseau JP, and Le LQ. (2019). Investigating col6a3 as a novel therapeutic target for neurofibroma development (poster). UTSouthwestern Summer Research Fellowship (SURF) Program. Dallas, United States.
  • * Highly Qualified Trained Personnel Brosseau JP, Liao CP, Wang Y, Ramani V, Vandergriff T, Lee M*, Patel A*, Ariizumi K and Le LQ. (2019). NF1 Heterozygosity Fosters de Novo Tumorigenesis, but Impairs Malignant Transformation (poster). Society for Investigative Dermatology 77th Annual Meeting. Chicago, United States.
  • (2019). Recent Progress in Cancer Biology. Beta Beta Beta Meeting (national biology honors society) Dallas Baptist University. Dallas, United States.
  • (2019). Taking advantage of single cell RNA sequencing: From profiling to drug repurposing (selected for micro-talk + poster). Riboclub 20th Annual Meeting. Orford, Canada.
  • (2019). The Molecular and Cellular Mechanisms Favoring the Benign State of a Tumor. Invited by the Department of Biochemistry Université de Sherbrooke. Sherbrooke, Canada.
  • (2019). The Molecular and Cellular Mechanisms Favoring the Benign State of a Tumor. Invited by the Department of Biochemistry Université de Sherbrooke. Canada.
  • (2019). Tumor Suppressor Gene Heterozygous Microenvironment in Cancer Development. 3rd international cancer conference and Expo. Baltimore, United States.
  • (2018). Hereditary Cancer Syndrome: Thinking outside the box. UTSouthwestern Center for Regenerative Science and Medicine Work in progress seminar. Dallas, United States.
  • (2018). Hereditary Cancer Syndrome: Thinking outside the box. UTSouthwestern Center for Regenerative Science and Medicine Work In Progress Seminar Series. Dallas, United States.
  • * Highly Qualified Trained Personnel. Brosseau JP, Liao CP, Wang Y, Ramani V, Vandergriff T, Lee M*, Patel A*, Ariizumi K and Le LQ. (2018). NF1 Heterozygosity Fosters de Novo Tumorigenesis, but Impairs Malignant Transformation (poster). Joint Global Neurofibromatosis Conference. Paris, United States.
  • (2018). The contribution of microenvironment to tumorigenesis in Familial Tumor syndrome: The example of Neurofibromatosis type I. UTSouthwestern Dermatology Departmental Meetings Seminar Series. Dallas, United States.
  • (2018). The contribution of microenvironment to tumorigenesis in Familial Tumor syndrome: The example of Neurofibromatosis type I. UTSouthwestern Dermatology Departmental Meetings seminar serie. Dallas, United States.
  • (2017). Contribution of fibroblasts to Neurofibroma development. UTSouthwestern Dermatology Departmental Meetings Seminar Series. Dallas, United States.
  • * Highly Qualified Trained Personnel. Brosseau JP, Nguyen T*, Liao CP and Le LQ. (2017). NG2 – Col VI axis: The missing gap in Neurofibroma development (poster). Neurofibromatosis conference. Washington, United States.
  • * Highly Qualified Trained Personnel. Brosseau JP, Nguyen T*, Liao CP and Le LQ. (2017). NG2 – Col VI axis: The missing gap in Neurofibroma development (poster). Keystone Meeting “Inflammation, Injury and Fibrosis”. Salt Lake City, United States.
  • (2017). The NF1+/- microenvironment: New friends and old foes. UTSouthwestern Dermatology Departmental Meetings seminar serie. Dallas, United States.
  • (2017). The NF1+/- microenvironment: New friends and old foes. UTSouthwestern Dermatology Departmental Meetings Seminar Series. Dallas, United States.
  • (2017). The role of tumor microenvironment in cutaneous Neurofibroma and Squamous cell carcinoma. UTSouthwestern Dermatology Departmental Meetings seminar serie. Dallas, United States.
  • (2017). The role of tumor microenvironment in cutaneous Neurofibroma and Squamous cell carcinoma. UTSouthwestern Dermatology Departmental Meetings Seminar Series. Dallas, United States.
  • (2016). Alternative Splicing in Cancer: Noise or Functional?. University of Texas at Dallas. Dallas, United States.
  • (2016). Contribution of fibroblasts to Neurofibroma development. UTSouthwestern Dermatology Departmental Meetings seminar serie. Dallas, United States.
  • (2014). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Micheal Potente lab at the Max Planck Institute for Heart and Lung Research. Frankfurt, Germany.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Max Planck Institute for Developmental Biology. Tuebingen, Germany.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Khokha and Rottapel at the University of Toronto. Toronto, Canada.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Izzauralde lab at the Max Planck Institute for Developmental Biology. Tuebingen, Germany.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Egeblad and Krainer lab at Cold Spring Harbor Laboratories. Long Island, Canada.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Lee lab at the University of Ottawa. Ottawa, Canada.
  • (2013). Alternative Splicing in Cancer: Noise or Functional?. Invited by the Vanharanta lab at the University of Cambridge. Cambridge, United Kingdom.
  • (2013). Alternative splicing in cancer: Noise or Driver?. Monthly Max Planck Institute Seminar Series. Tuebingen, Germany.
  • (2011). EarthQuaking the ovarian tumor microenvironment. Monthly Riboclub session. Sherbrooke, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.